Association between colchicine resistance and vitamin D in familial Mediterranean fever

Ozer I., Mete T., Sezer O. T., Ozgen G. K., Kucuk G. O., Kaya C., ...More

RENAL FAILURE, vol.37, no.7, pp.1122-1125, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 7
  • Publication Date: 2015
  • Doi Number: 10.3109/0886022x.2015.1056064
  • Journal Name: RENAL FAILURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1122-1125
  • Keywords: Colchicines, vitamin D, familial Mediterranean fever, resistance to colchicines, FMF, AMYLOIDOSIS
  • Ondokuz Mayıs University Affiliated: Yes


Although colchicines are the only effective treatment of familial Mediterranean fever (FMF), resistance to colchicines (CR) which is observed in up to 30% of the patients is still a problem. Clinically, resistance to colchicine is defined as three or more attacks within the last 6 months period while using >= 2 mg/day colchicine. Previous studies have shown decreased vitamin D levels in FMF patients compared with healthy controls. The aim of this study is to evaluate whether vitamin D levels differ between CR and non-CR FMF patients. This study included 64 FMF patients who were being followed in Nephrology Clinic of Samsun Research and Education Hospital for at least 1 year. FMF was diagnosed according to the criteria defined by Livneh et al. Serum 25-hydroxy vitamin D (25-OHD) concentration (ng/mL) was detected in all FMF patients who were not in an acute attack period. From 64 patients 29 were accepted as CR. Mean 25-OHD level was 9.39 +/- 1.00 ng/mL in CR patients and 18.48 +/- 1.09 ng/mL in colchicine responsive patients (p<0.001). Plasma vitamin D levels were significantly lower in colchicine resistant patients. Vitamin D deficiency may be a factor in etiopathogenesis of CR. Studies in larger patient samples that particularly evaluate the response to vitamin D replacement in CR FMF patients are needed.